Literature DB >> 28704327

Examining the Effects of Time to Diagnosis, Income, Symptoms, and Incidental Detection on Overall Survival in Epithelial Ovarian Cancer: Manitoba Ovarian Cancer Outcomes (MOCO) Study Group.

Alon D Altman1, Pascal Lambert, Allison J Love, Donna Turner, Robert Lotocki, Erin Dean, Shaundra Popowich, Mark W Nachtigal.   

Abstract

OBJECTIVE: The primary objectives of this study were to analyze data on time to diagnosis and correlate this with overall survival. We secondarily analyzed the effects of emergency room visits, symptoms, incidental findings, residence, socioeconomic status, and residual disease on overall survival.
METHODS: This retrospective population-based descriptive cohort study examined all invasive ovarian cancer cases in Manitoba, Canada, between 2004 and 2010. Clinicopathologic, socioeconomic, and outcome data were collected. Analysis was performed with Cox and logistic regression stratified by early and late stage.
RESULTS: Six hundred eighty-seven ovarian cancer patients were identified, with a final cohort of 601 patients: 210 with early-stage (1/2) and 391 with late-stage (3/4) disease. No presenting symptoms were associated with survival outcome. Poorer survival was associated with increasing age (P = 0.0016) and neoadjuvant chemotherapy (P = 0.0037). Higher income within the urban setting was also associated with a survival advantage (P = 0.0037), whereas initial presentation to the emergency room (P = 0.0399) was associated with decreased survival. Finally, for advanced-stage disease, incidental diagnosis had a significantly improved overall survival (hazard ratio, 0.424; 95% confidence interval, 0.27-0.67; P = 0.0003), even when accounting for confounding factors. Time from first presentation to diagnosis was associated with survival (P = 0.0309).
CONCLUSIONS: This study found that time to diagnosis did not negatively impact overall survival, although there was an association. Age, morphology, treatment type, residual disease, medical comorbidities, and income were significant prognostic factors. This is the first study to show a survival advantage to incidentally finding an ovarian cancer. Further research is needed on the outcomes of pelvic examination.

Entities:  

Mesh:

Year:  2017        PMID: 28704327     DOI: 10.1097/IGC.0000000000001074

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.

Authors:  Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

2.  Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman StudyTM.

Authors:  Alicia Tone; Talin Boghosian; Alison Ross; Elisabeth Baugh; Alon D Altman; Lesa Dawson; Frances Reid; Cailey Crawford
Journal:  Curr Oncol       Date:  2022-05-05       Impact factor: 3.109

3.  Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France.

Authors:  Marius Huguet; Lionel Perrier; Olivia Bally; David Benayoun; Pierre De Saint Hilaire; Dominique Beal Ardisson; Magali Morelle; Nathalie Havet; Xavier Joutard; Pierre Meeus; Philippe Gabelle; Jocelyne Provençal; Céline Chauleur; Olivier Glehen; Amandine Charreton; Fadila Farsi; Isabelle Ray-Coquard
Journal:  BMC Health Serv Res       Date:  2018-01-04       Impact factor: 2.655

4.  Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  James Dilley; Matthew Burnell; Aleksandra Gentry-Maharaj; Andy Ryan; Christina Neophytou; Sophia Apostolidou; Chloe Karpinskyj; Jatinderpal Kalsi; Tim Mould; Robert Woolas; Naveena Singh; Martin Widschwendter; Lesley Fallowfield; Stuart Campbell; Steven J Skates; Alistair McGuire; Mahesh Parmar; Ian Jacobs; Usha Menon
Journal:  Gynecol Oncol       Date:  2020-06-17       Impact factor: 5.482

Review 5.  The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer.

Authors:  Mark W Nachtigal; Alon D Altman; Rajat Arora; Frank Schweizer; Gilbert Arthur
Journal:  Cancers (Basel)       Date:  2022-07-07       Impact factor: 6.575

6.  Prehospital care for ovarian cancer in Catalonia: could we do better in primary care? Retrospective cohort study.

Authors:  Carmen Vela-Vallespín; Paula Manchon-Walsh; Luisa Aliste; Josep M Borras; Mercè Marzo-Castillejo
Journal:  BMJ Open       Date:  2022-07-22       Impact factor: 3.006

7.  Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States.

Authors:  Sarah P Huepenbecker; Charlotte C Sun; Shuangshuang Fu; Hui Zhao; Kristin Primm; Sharon H Giordano; Larissa A Meyer
Journal:  Cancer       Date:  2021-08-04       Impact factor: 6.860

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.